Cited by 555Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsDementia and Cognitive Impairment Research

Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE

Open access
Parhizkar, Samira, Arzberger, Thomas, Brendel, Matthias, Kleinberger, Gernot, Deussing, Maximilian, Focke, Carola, Nuscher, Brigitte, Xiong, Monica +21 more·2019·Nature Neuroscience

Abstract

Coding variants in the triggering receptor expressed on myeloid cells 2 (TREM2) are associated with late-onset Alzheimer's disease (AD). We demonstrate that amyloid plaque seeding is increased in the absence of functional Trem2. Increased seeding is accompanied by decreased microglial clustering around newly seeded plaques and reduced plaque-associated apolipoprotein E (ApoE). Reduced ApoE deposition in plaques is also observed in brains of AD patients carrying TREM2 coding variants. Proteomic analyses and microglia depletion experiments revealed microglia as one origin of plaque-associated ApoE. Longitudinal amyloid small animal positron emission tomography demonstrates accelerated amyloidogenesis in Trem2 loss-of-function mutants at early stages, which progressed at a lower rate with aging. These findings suggest that in the absence of functional Trem2, early amyloidogenesis is accelerated due to reduced phagocytic clearance of amyloid seeds despite reduced plaque-associated ApoE.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41593-018-0296-9

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Numerous studies targeting members of the TREM2/TYROBP pathway (Trem2, Tyrobp, and miR155) support beneficial outcomes associated with maintenance and/or restoration of homeostatic functions of microglia.

    “Support for beneficial outcomes associated with maintenance and/or restoration of homeostatic functions of microglia comes from the numerous studies targeting the members of this pathway, including Trem2,48,50–52 Tyrobp,53,54 and miR155.41,55”

    From Microglial <i>INPP5D</i> limits plaque formation and glial reactivity in the PSAPP mouse model of Alzheimer's disease (2023) · cites this paper as [51]

    The Discussion (page unavailable) says functional TREM2 may protect against early amyloid seeding by enabling microglia to cluster around and clear newly seeded plaques. But it also says TREM2 loss leaves microglia locked in a homeostatic state while reducing plaque clearance. The paper therefore supports a potential benefit of TREM2 function, not a benefit specifically from maintaining or restoring microglial homeostasis. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Conflicting results have been reported regarding amyloid plaque deposition and the effect of TREM2 loss, suggesting that the effect of TREM2 on Ab deposition may be dependent on age, sex, and the model utilized.

    “Conflicting results have been reported regarding amyloid plaque deposition and the effect of TREM2 loss [7,8,9,10,11], suggesting that the effect of TREM2 on Ab deposition may be dependent on age, sex, and the model utilized.”

    From TREM2-Deficient Microglia Attenuate Tau Spreading In Vivo (2023) · cites this paper as [10]

    The Results section (“Loss of Trem2 function changes the kinetics of amyloidogenesis”; page unavailable) explicitly says earlier studies reported conflicting plaque-burden results and finds that the effect of Trem2 loss changes with age. The Online Methods (“Transgenic mice”; page unavailable) notes sex-related variability in plaque deposition, but the paper does not show that sex changes the effect of Trem2 loss. It uses two loss-of-function models without establishing that the effect depends on the model. (LLM, conf=0.87)

    Experimental — accuracy not yet measured
  • Manipulation of Trem2, Tyrobp, Cx3cl1/Cx3cr1, IL1β, and IFN-γ have opposing effects on amyloid and tau pathologies.

    “Indeed, manipulation of expression of Trem2, Tyrobp, Cx3cl1/Cx3cr1, IL1β, and IFN-γ have all been shown to have opposing effects on amyloid and tau pathologies [49–51, 55–65].”

    From Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways (2022) · cites this paper as [58]

    The Results section (‘Increased amyloid plaque seeding in the absence of functional Trem2’; page unavailable) reports increased amyloidogenesis when Trem2 function is lost. The paper does not establish an opposing effect on tau pathology or effects of manipulating Tyrobp, Cx3cl1/Cx3cr1, IL1β, or IFN-γ, so it supports only the Trem2–amyloid portion of the attributed claim. (LLM, conf=0.87)

    Experimental — accuracy not yet measured
  • The dichotomy of immune effects on amyloid and tau has been demonstrated in multiple models of Trem2 and Tyrobp.

    “More recently, this dichotomy has been elegantly demonstrated in multiple models of Trem2 and Tyrobp [49–51, 55–59].”

    From Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways (2022) · cites this paper as [58]

    The Results section, “Increased amyloid plaque seeding in the absence of functional Trem2” (page unavailable), reports increased amyloidogenesis in a second TREM2 loss-of-function model, supporting the TREM2–amyloid part of the claim. This paper does not demonstrate the claimed contrast between immune effects on amyloid and tau, or report a TYROBP model. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • In studies of Trem2 deficiency, differences were dependent on early versus later disease stages.

    “A similar interpretation could be developed from the studies of Trem2 deficiency, as differences were dependent on early versus later disease stages.50,51,57,58”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Parhizkar, S., Arzberger, T., Brendel, M., Kleinberger, G., Deussing, M., Focke, C., Nuscher, B., Xiong, M., Ghasemigharagoz, A., Katzmarski, N., Krasemann, S., Lichtenthaler, S. F., Müller, S. A., Colombo, A., Monasor, L. S., Tahirovic, S., Herms, J., Willem, M., Pettkus, N., Butovsky, O., Bartenstein, P., Edbauer, D., Rominger, A., Ertürk, A., Grathwohl, S. A., Neher, J. J., Holtzman, D. M., Meyer-Luehmann, M., & Haass, C.
Affiliations
  • Ludwig-Maximilians-Universität München (DE)
  • German Center for Neurodegenerative Diseases (DE)
  • Munich Cluster for Systems Neurology (DE)
  • Washington University in St. Louis (US)
  • Institut für Schlaganfall- und Demenzforschung (DE)
  • University of Freiburg (DE)
  • Brigham and Women's Hospital (US)
  • University Hospital of Bern (CH)
  • Hertie Institute for Clinical Brain Research (DE)
Corresponding author
Haass, Christian
Venue
Nature Neuroscience
Published
2019-01-07
Volume
22
Issue
2
Pages
191-204
ISSN
  • 1097-6256 (ISSN-L)
  • 1546-1726
OpenAlex
W2907318708
Cited by
555
References
60
Citations by year
2026: 50 · 2025: 70 · 2024: 64 · 2023: 82 · 2022: 89 · 2021: 82 · 2020: 80 · 2019: 38
FWCI
34.38
Type
journal article
Language
en
Open access
Locations
  • Nature Neuroscience (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
Funders
  • Agence Nationale de la Recherche (ANR-16-COEN-0005)
  • National Institute on Aging (R01AG047644, R01AG051812, RF1AG047644, R01AG054672)
  • National Institute of Neurological Disorders and Stroke (R01NS090934, R01NS088137, RF1NS090934)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
TREM2, Alzheimer's disease, amyloid seeding, amyloid plaques, apolipoprotein E, microglia, microglial activation, amyloid clearance, amyloidogenesis, phagocytosis, microglia depletion
MeSH terms
Alzheimer Disease, Amyloid, Animals, Apolipoproteins E, Brain, Disease Models, Animal, Genotype, Humans, Membrane Glycoproteins, Mice, Transgenic, Phagocytosis, Receptors, Immunologic, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Microglia, Mice, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review